Indian Pharma Giants Navigate Turbulent US Generics Market

Share the post :

Indian Pharma Giants Navigate Turbulent US Generics Market

In a turbulent turn of events, Indian pharmaceutical giants are grappling with escalating challenges in the US generics market, exacerbated by a sharp double-digit decline in drug prices observed from April to June 2024. The latest data from the National Average Drug Acquisition Cost (NADAC) underscores a formidable hurdle for companies heavily dependent on this segment.

Citi Research’s latest analysis highlights Sun Pharmaceutical Industries Ltd and Torrent Pharma as resilient leaders amid the storm, favored for their adept handling of pricing pressures. However, the outlook remains grim for Aurobindo Pharma, Cipla, Dr Reddy’s Laboratories, and Lupin, all of whom face intensified scrutiny and potential downturns in earnings.

Supply disruptions triggered by import warnings at select manufacturing facilities, coupled with aggressive production increases from Indian and Chinese competitors, have further destabilized the market. These factors have momentarily stabilized drug prices but have also introduced unprecedented volatility.

In response to these challenges, companies are strategically maneuvering to mitigate risks. Lupin’s strategic launch of Myrbetriq for overactive bladder aims to diversify its portfolio and cushion against pricing vulnerabilities, showcasing a proactive approach amidst market uncertainty.

As the sector navigates these uncharted waters, stakeholders and investors are advised to closely monitor developments to gauge the resilience and strategic agility of these pharmaceutical giants in safeguarding their market positions and sustaining growth amidst turbulent market conditions.

also read  : Supreme Court Issues Notices on NEET UG Malpractice Petitions, Sets Hearing for July 8

Ahmed Mainul

My self Ahmed Mainul Mondal, and I'm the founder of the hospitality career profile website. I'm writing blogs and news posts as per user preferences.

1 thought on “Indian Pharma Giants Navigate Turbulent US Generics Market”

Leave a Comment